

**NAACCR Call for Data 2020**  
**Data Selection Criteria Based on Case Reportability**  
**1995-2021**

The data selection criteria for use in identifying cases for inclusion in data submissions for CiNA data or registry certification have been developed to exactly match the NPCR Call for Data case definition.

**Diagnosis Years:** Include cases diagnosed in all residents of your catchment area beginning with your reference year (e.g., 1995) through December 31, 2020 (required) or December 31, 2021 (requested for evaluation). For guidance on residency, refer to page 19 of NAACCR Standards for Cancer Registries, Volume II, Record Layout Version 22.

2021 data is requested for evaluation purposes *and* for early assessment of the continuing impact of covid-19 on cancer.

**Reportable Diagnoses:** All histologies with a behavior code of “2” or “3” (or in some cases behavior “0” or “1”, see Table 2 for details) in the *International Classification of Diseases for Oncology*, Third Edition (ICD-O-3) are included with the exceptions specified below.

**Exclusion Criteria**

*Exclude* neoplasms of the skin (C44.0–C44.9) with the following histologies:

- 8000-8005 Neoplasms, malignant, NOS of the skin (C44.0-C44.9)
- 8010-8046 Epithelial carcinomas of the skin (C44.0-C44.9)
- 8050-8084 Papillary and squamous cell carcinomas of the skin (C44.0-C44.9)
- 8090-8110 Basal cell carcinomas of the skin (C44.0-C44.9)

**Do not exclude skin lesions that occur at the mucoepidermoid sites** [vagina (C52.9), clitoris (C51.2), vulva (C51.0-51.9), prepuce (C60.0), penis (C60.9), and scrotum (C63.2)].

*Exclude* carcinoma in situ of the cervix (C53.0-C53.9 any morphology and/2).

*Exclude* prostate intraepithelial neoplasia, grade III (PIN III) (C61.9. 8148/2) after January 1, 2001.

*Exclude* squamous intraepithelial neoplasia, grade III (8077/2) of the following sites: anus (C21.0 and C21.1, AIN III), cervix (C53, CIN III), vagina (C52.9, VAIN III), and vulvar (C51, VIN III).

**NEW EXCLUSION:** The borderline tumors listed in Table 1 (Page 2) are no longer required for submission.

**Table 1. Histological Diagnoses Considered Invasive under ICD-O-2 but not ICD-O-3 and no longer required for submission**

<b>Descriptive terms and topography codes</b>	<b>ICD-O-3</b>
Serous cystadenoma, borderline malignancy (C56.9)	8442/1
Serous tumor, NOS, of low malignant potential (C56.9)	8442/1
Papillary cystadenoma, borderline malignancy (C56.9)	8451/1
Serous papillary cystic tumor of borderline malignancy (C56.9)	8462/1
Papillary serous cystadenoma, borderline malignancy (C56.9)	8462/1
Papillary serous tumor of low malignant potential (C56.9)	8462/1
Atypical proliferative papillary serous tumor (C56.9)	8462/1
Mucinous cystic tumor of borderline malignancy (C56.9)	8472/1
Mucinous cystadenoma, borderline malignancy (C56.9)	8472/1
Pseudomucinous cystadenoma, borderline malignancy (C56.9)	8472/1
Mucinous tumor, NOS, of low malignant potential (C56.9)	8472/1
Papillary mucinous cystadenoma, borderline malignancy (C56.9)	8473/1
Papillary pseudomucinous cystadenoma, borderline malignancy (C56.9)	8473/1
Papillary mucinous tumor of low malignant potential (C56.9)	8473/1

### **Inclusion Criteria**

The cases to be included reflect standards for reportability during the year of diagnosis and vary by year of diagnosis as a result. These changes are based upon NPCR and NAACCR reportable condition standards and changes in behavior coding between ICD-O 2 and ICD-O 3.

Cases diagnosed beginning January 1, 2004: All nonmalignant primary intracranial and central nervous system tumors with a behavior code of “0” or “1” are reportable. However, benign and borderline tumors of the cranial bones (C410) are not reportable. For further guidance, please refer to Table 2 below.

Include all cases of pilocytic astrocytoma [9421]. If necessary, convert behavior code to /3 except optic nerve (C72.3) cases diagnosed January 1, 2018 or later. When the Primary Site is optic nerve, the behavior is non-malignant per the Solid Tumor Manual 2018. Pilocytic astrocytoma of the optic nerve (may be referred to as optic glioma) diagnosed prior to 2018 should have a behavior of /3.

**Table 2. Required Sites for Benign and Borderline Primary Intracranial and Central Nervous System Tumors**

<b>General Term</b>	<b>Specific Sites</b>	<b>ICD-O-3</b>
Meninges	Cerebral meninges	C70.0
	Meninges, NOS	C70.9
	Spinal meninges	C70.1
Brain	Cerebrum	C71.0
	Frontal lobe	C71.1
	Temporal lobe	C71.2
	Parietal lobe	C71.3
	Occipital lobe	C71.4
	Ventricle, NOS	C71.5
	Cerebellum, NOS	C71.6
	Brain stem	C71.7
	Overlapping lesion of brain	C71.8
	Brain, NOS	C71.9
	Spinal cord, cranial nerves, and other parts of the central nervous system	Spinal cord C720
Cauda equine		C72.1
Olfactory nerve		C72.2
Optic nerve		C72.3
Acoustic nerve		C72.4
Cranial nerve, NOS		C72.5
Overlapping lesion of brain and central nervous system		C72.8
Nervous system, NOS		C72.9
Pituitary, craniopharyngeal, duct, and pineal Gland	Pituitary gland	C75.1
	Craniopharyngeal duct	C75.2
	Pineal gland	C75.3